Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Conditions: Parkinson's Disease
Interventions: NR2B NMDA Antagonist CP-101,606 (traxoprodil); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Congestive Heart Failure, Hypotension
Interventions: True Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Disease of Liver and Bile Duct
Interventions: vibration controlled transient elastography (VCTE); Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acne Scars
Interventions: Fraxel Restore (Non-ablative Fractional Laser), Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder, Bipolar Depression, Manic Depression
Interventions: Uridine, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 13 Years to 21 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Down Syndrome
Interventions: Down Syndrome Clinic to You (DSC2U); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year and older
Enrollment: 281 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Methamphetamine Dependence
Interventions: Bupropion, Placebo; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 9 more

Conditions: Immunoglobulin A Nephropathy, IgAN
Interventions: Ravulizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 39
States / cities: Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more

Conditions: Cytomegalovirus Infection
Interventions: Placebo, Valganciclovir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 30 Days
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more

Conditions: Healthy Adults
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Glaucoma
Interventions: AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution, AR-102 0.03% Ophthalmic Solution, AR-102 Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more

Conditions: Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
Interventions: Naltrexone, Modafinil, Placebo; Drug
Lead sponsor: Kyle Kampman; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Scar Prevention
Interventions: EXC 001, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Healthy Subjects, Cardiac Repolarization
Interventions: Placebo, ASP1941, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Screen Time Exposure
Interventions: Human-developed negative body image warning, Voluntary warning, Human-developed depression and anxiety warning, Human-developed addiction warning, Human-developed sleep warning, Human-developed mental health harms to young people warning, Human-developed warning that social media has not been proven safe, Control message, California's proposed social media warning, Artificial-intelligence-developed depression and anxiety warning, Artificial-intelligence-developed negative body image warning, Artificial-intelligence-developed addiction warning, Artificial-intelligence-developed sleep warning, Artificial-intelligence-developed mental health harms to young people warning, Artificial-intelligence-developed warning that social media has not been proven safe; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 29 Years
Enrollment: 1,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV
Interventions: Care management; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Blood Flow Restriction
Interventions: Blood Flow Restriction Therapy, Traditional Therapy; Device · Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Labor Complication, Pregnancy Related
Interventions: Prophylactic manual rotation, Sham rotation; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: LY3819253, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 42
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 32 more

Conditions: Knee Osteoarthritis
Interventions: Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline; Device · Drug
Lead sponsor: Dustin L. Richter, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Rheumatoid Arthritis
Interventions: SKI-O-703, Placebo; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Beverly Hills, California • Upland, California • Miami Lakes, Florida + 9 more

Conditions: Brain Injuries
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 20
States / cities: Mobile, Alabama • Tucson, Arizona • Colton, California + 16 more

Search by objective public record fields.

Atrasentan in Patients With IgA Nephropathy

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

Comparison of 1550nm Fractional Laser Alone Versus in Combination With Microneedling for the Treatment of Acne Scars

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

An Online Health Tool About Down Syndrome: Down Syndrome Clinic to You

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Ocular Hypotensive Efficacy of AR-102

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

Reactions to Social Media Warning Labels Among Teens and Young Adults

Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care

BFR Therapy in Patients With Rotator Cuff Tears

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

PROphylactic Manual RotatIon in the Second stagE of Labor

LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Study of NNZ-2566 in Patients With Traumatic Brain Injury